a study to assess the safety and efficacy of centhaquine in hypovolemic shock patients

Conditions: Hypovolemic Shock

Summary: this is a prospective, multi-centric, open-labeled, phase-iv clinical study to evaluate the safety and efficacy of centhaquine citrate (lyfaquin™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. centhaquine has been found to be an effective resuscitative agent in rat, rabbit, and swine models of hemorrhagic shock. it has demonstrated the ability to decrease blood lactate levels, increase mean arterial pressure, enhance cardiac output, and reduce mortality rates. the increase in cardiac output during resuscitation is primarily attributed to an augmentation in stroke volume. centhaquine exerts its effects by acting on the venous α2b-adrenergic receptors, which enhances venous return to the heart. additionally, it produces arterial dilation by targeting central α2a-adrenergic receptors, thereby reducing sympathetic activity and systemic vascular resistance.

this study will enroll approximately 400 patients aged 18 years or older with hypovolemic shock and a systolic blood pressure of 90 mmhg or lower upon admission to the hospital. these patients will continue to receive standard shock treatment, including endotracheal intubation, fluid resuscitation, and vasopressors. the trial seeks to answer several key questions: is centhaquine safe to use in patients with hypovolemic shock? can centhaquine improve blood pressure, lactate levels, and base deficit, and reduce mortality? participants will receive centhaquine in addition to the standard of care. centhaquine will be administered intravenously in 100 ml of normal saline at a dose of 0.01 mg/kg of body weight over a period of one hour. a second dose will be given if the systolic blood pressure remains at or below 90 mmhg, but not before 4 hours have passed since the previous dose. the total number of doses within 24 hours will not exceed 3, and centhaquine administration may continue for up to two days after enrollment. each patient will be closely monitored throughout their hospitalization and followed until discharge or up to seven days from enrollment, whichever comes first. the trial will assess safety and efficacy parameters according to a predefined schedule of visits. the baseline characteristics of the patients in different groups will be compared using statistical tests such as the chi-square test for categorical variables and the unpaired t-test for continuous variables. changes in dichotomous variables between groups from baseline to follow-ups will be analyzed using mcnemar's test. survival rates will be measured using kaplan-meier survival analysis, and univariate and multiple cox-regression analysis will be employed to determine hazard ratios and their 95% confidence intervals for patient survival. the trial results will be presented as mean±sem (median, minimum, and maximum) values and percentages.

Eligibility criteria:
inclusion criteria • adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or icu with systolic blood pressure ≤ 90 mmhg at presentation and continue to receive standard shock treatment. blood lactate level indicative of hypovolemic shock (\>2.0 mmol/l). exclusion criteria * development of any other terminal illness not associated with hypovolemic shock during the study duration. * patient with altered consciousness not due to hypovolemic shock and comatose patient. • known pregnancy. * cardiopulmonary resuscitation (cpr) before enrollment. * presence of a do not resuscitate order. * patient is participating in another interventional study. * patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure, or aids.

Keywords: shock hypovolemia hemorrhage blood pressure resuscitation centhaquine adrenergic